Reply to: "Comment on 'Drug survival of secukinumab and ixekizumab for moderate-to-severe plaque psoriasis'"

Alexander Egeberg^*, Lars Erik Bryld, Lone Skov

^*Corresponding author af dette arbejde

Publikation: Bidrag til tidsskrift › Kommentar/debat › Forskning

Originalsprog	Engelsk
Artikelnummer	e379
Tidsskrift	Journal of the American Academy of Dermatology
Vol/bind	85
Udgave nummer	6
DOI	https://doi.org/10.1016/j.jaad.2019.05.082
Status	Udgivet - dec. 2021

Adgang til dokumentet

@article{96dbaa8b4fe54bd8bf04001875008547,

title = "Reply to: {"}Comment on 'Drug survival of secukinumab and ixekizumab for moderate-to-severe plaque psoriasis'{"}",

author = "Alexander Egeberg and Bryld, {Lars Erik} and Lone Skov",

year = "2021",

month = dec,

doi = "10.1016/j.jaad.2019.05.082",

language = "English",

volume = "85",

journal = "Journal of the American Academy of Dermatology",

issn = "0190-9622",

publisher = "Elsevier",

number = "6",

}

TY - JOUR

T1 - Reply to: "Comment on 'Drug survival of secukinumab and ixekizumab for moderate-to-severe plaque psoriasis'"

AU - Egeberg, Alexander

AU - Bryld, Lars Erik

AU - Skov, Lone

PY - 2021/12

Y1 - 2021/12

U2 - 10.1016/j.jaad.2019.05.082

DO - 10.1016/j.jaad.2019.05.082

M3 - Comment/debate

C2 - 31170436

SN - 0190-9622

VL - 85

JO - Journal of the American Academy of Dermatology

JF - Journal of the American Academy of Dermatology

IS - 6

M1 - e379

ER -